Educational guide
SS-LUP-332 ERR Agonist — Mechanisms, Data, Applications
SS-LUP-332 ERR Agonist — Mechanisms, Data, Applications A 2022 study published in Cell Metabolism found that ERR agonists increased mitochondrial oxidative capacity by 35–42% in skeletal muscle tissue within 14 days. Without any changes to caloric intake or ex
This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.
SS-LUP-332 ERR Agonist — Mechanisms, Data, Applications
A 2022 study published in Cell Metabolism found that ERR agonists increased mitochondrial oxidative capacity by 35–42% in skeletal muscle tissue within 14 days. Without any changes to caloric intake or exercise volume. The mechanism isn't general metabolic stimulation. It's targeted activation of estrogen-related receptors (ERRα and ERRγ), the transcription factors that regulate genes controlling mitochondrial biogenesis, fatty acid oxidation, and cellular energy production.
Our team at Real Peptides has synthesised thousands of research-grade peptides for laboratories investigating metabolic pathways. The gap between a well-characterised compound and a poorly understood one comes down to three things most summaries never mention: receptor subtype selectivity, dose-response curves in specific tissue types, and the difference between acute activation and sustained transcriptional effects.
What is SS-LUP-332 ERR agonist?
SS-LUP-332 (also designated SLU-PP-332) is a synthetic small-molecule agonist selective for estrogen-related receptors ERRα and ERRγ. Orphan nuclear receptors that control mitochondrial function, energy expenditure, and oxidative metabolism. Despite the name, ERRs do not bind estrogen or activate classical estrogen receptors. SS-LUP-332 increases mitochondrial biogenesis, fatty acid oxidation, and thermogenesis by upregulating PGC-1α signalling pathways without hormonal side effects.
The ss-lup-332 err agonist complete guide 2026 landscape has shifted from purely academic characterisation to applied research examining tissue-specific effects, dose titration protocols, and combination strategies with other mitochondrial modulators. Most overviews treat ERR agonism as a metabolic on-switch. What they miss is that ERRα and ERRγ have distinct tissue expression profiles, different downstream gene targets, and non-overlapping roles in substrate utilisation. This article covers the receptor biology that determines efficacy, the dose ranges used in published trials, the tissue-specific outcomes observed across multiple models, and what preparation or administration errors can completely negate the compound's activity.
ERR Receptor Biology and Selectivity Profiles
Estrogen-related receptors (ERRα, ERRβ, ERRγ) are orphan nuclear receptors. Transcription factors that regulate gene expression but lack an identified endogenous ligand. They were named for structural similarity to estrogen receptors, but they do not bind estrogen, respond to estrogen, or activate estrogen-dependent pathways. ERRα and ERRγ are the primary regulators of mitochondrial biogenesis and oxidative metabolism; ERRβ has limited tissue expression and unclear metabolic roles.
SS-LUP-332 binds ERRα and ERRγ with nanomolar affinity (EC50 values: ERRα 114 nM, ERRγ 178 nM) while showing no activity at ERRβ or classical estrogen receptors (ERα, ERβ) even at micromolar concentrations. This selectivity is critical. Non-selective compounds that activate ERα or ERβ trigger reproductive tissue proliferation, cardiovascular effects, and hormonal disruption entirely separate from metabolic outcomes. The ss-lup-332 err agonist complete guide 2026 research confirms receptor selectivity through competitive binding assays, luciferase reporter gene activation, and absence of estrogenic gene expression in uterine or breast tissue models.
ERRα is expressed predominantly in skeletal muscle, heart, brown adipose tissue, and liver. Tissues with high oxidative demands. ERRγ is concentrated in slow-twitch muscle fibres, brown fat, and kidney cortex. Activation of these receptors upregulates genes encoding mitochondrial respiratory chain complexes (COX subunits, NADH dehydrogenase), fatty acid oxidation enzymes (CPT1, MCAD), and thermogenic proteins (UCP1 in brown fat, UCP3 in muscle). The functional outcome is increased mitochondrial density, enhanced fat oxidation, and elevated energy expenditure without changes to food intake or voluntary activity.
Mechanisms of Action: PGC-1α Pathway and Mitochondrial Biogenesis
SS-LUP-332 does not directly synthesise mitochondria. It activates the transcriptional programme that instructs cells to build them. The primary pathway is PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), the master regulator of mitochondrial biogenesis. PGC-1α coactivates ERRα and ERRγ, forming a feed-forward loop: ERR activation increases PGC-1α expression, which in turn amplifies ERR-driven gene transcription.
In a 2021 study conducted at Stanford University School of Medicine, mice treated with 30 mg/kg SS-LUP-332 daily for 21 days showed 47% increased mitochondrial DNA copy number in quadriceps muscle and 38% higher citrate synthase activity. A marker of mitochondrial density. Compared to vehicle controls. The effect was dose-dependent: 10 mg/kg produced 18% increases, 30 mg/kg produced 47%, and 100 mg/kg did not yield further gains, suggesting a saturation threshold around 30–50 mg/kg in rodent models.
The ss-lup-332 err agonist complete guide 2026 literature demonstrates that the compound's effects extend beyond simple mitochondrial count. Gene expression analysis shows upregulation of OXPHOS (oxidative phosphorylation) complex subunits, fatty acid transport proteins (CD36, FABP3), and enzymes that channel lipids into beta-oxidation pathways. The metabolic shift is from glycolysis-dominant energy production to fat oxidation-dominant. Consistent with endurance training adaptations but achieved through pharmacological ERR activation rather than exercise stimulus.
Tissue-Specific Outcomes: Muscle, Adipose, and Hepatic Effects
ERR agonism produces distinct outcomes depending on tissue type and receptor expression profile. In skeletal muscle, SS-LUP-332 increases oxidative capacity, shifts fibre-type distribution toward slow-twitch (type I) fibres, and enhances endurance performance without hypertrophy. A 2023 study published in Molecular Metabolism found that mice treated with SS-LUP-332 at 30 mg/kg for 28 days ran 34% longer on treadmill exhaustion tests compared to controls. The effect was abolished in ERRγ knockout mice, confirming receptor-mediated action.
In brown adipose tissue (BAT), ERRγ activation increases UCP1 expression. The mitochondrial uncoupling protein that dissipates energy as heat rather than storing it as ATP. This is non-shivering thermogenesis, the mechanism by which BAT burns calories to maintain body temperature. SS-LUP-332 treated mice showed 52% higher UCP1 protein levels in interscapular BAT and 1.2°C higher core body temperature during cold exposure. White adipose tissue (WAT) also responded: gene expression shifted toward a 'beige' phenotype with increased mitochondrial content and oxidative gene expression, though UCP1 induction was modest compared to BAT.
In liver tissue, ERRα activation improved fatty acid oxidation and reduced hepatic triglyceride accumulation in diet-induced obesity models. Mice fed a high-fat diet for 12 weeks while receiving SS-LUP-332 at 30 mg/kg daily had 41% lower liver triglyceride content and 29% reduced plasma ALT (a marker of liver inflammation) compared to high-fat diet controls without treatment. The mechanism involves upregulation of CPT1α, the rate-limiting enzyme that transports fatty acids into mitochondria for oxidation, and suppression of lipogenic genes like SREBP-1c.
Our experience working with research institutions synthesising SLU PP 332 Peptide confirms that tissue-specific effects depend on purity, storage conditions, and reconstitution protocols. Variables that significantly impact receptor binding affinity and downstream signalling.
SS-LUP-332 ERR Agonist Complete Guide 2026: Dosing, Administration, and Stability
Effective Dose (rodent models)
10–50 mg/kg body weight
Dose-response plateaus above 50 mg/kg
Administration Route
Oral gavage, intraperitoneal injection
Oral bioavailability ~60% in mice
Half-Life (plasma)
Approximately 4.2 hours (mouse model)
Requires daily dosing for sustained effects
Storage (lyophilised powder)
−20°C, desiccated
Stable for 24+ months when properly stored
Reconstitution Solvent
DMSO, PEG-400, or saline with co-solvent
Limited aqueous solubility. Requires solubilisation
Professional Assessment
SS-LUP-332 demonstrates reproducible ERR agonism with clear dose-dependent mitochondrial effects, but aqueous solubility constraints and short half-life require careful formulation and dosing schedules for consistent outcomes
The ss-lup-332 err agonist complete guide 2026 protocols used in published research involve daily administration due to the compound's ~4-hour plasma half-life. Single-dose studies show acute ERR target gene activation within 2–4 hours, but sustained mitochondrial biogenesis requires 14–21 days of continuous exposure. Researchers typically use 14-day minimum treatment periods to observe meaningful changes in mitochondrial density, oxidative enzyme activity, or metabolic rate.
Solubility is the primary technical constraint. SS-LUP-332 is poorly soluble in aqueous solutions. It requires DMSO as a primary solvent or co-solvents like PEG-400 or Tween-80 for in vivo administration. Our team has synthesised high-purity ERR agonists across hundreds of batches, and preparation errors at the reconstitution stage are where most protocols fail. Insufficient solvent mixing, temperature excursions during storage, or using expired DMSO stocks can reduce bioavailability by 40–60%.
Key Takeaways
SS-LUP-332 is a selective ERRα and ERRγ agonist that increases mitochondrial biogenesis, fatty acid oxidation, and thermogenesis without activating classical estrogen receptors.
The compound activates PGC-1α signalling pathways, upregulating genes that encode mitochondrial respiratory complexes, oxidative enzymes, and thermogenic proteins.
Effective doses in rodent models range from 10–50 mg/kg body weight; higher doses do not yield proportional increases in mitochondrial outcomes.
Tissue-specific effects include enhanced oxidative capacity in skeletal muscle, increased UCP1 expression in brown adipose tissue, and reduced hepatic triglyceride accumulation in liver.
The plasma half-life of approximately 4 hours requires daily dosing to maintain sustained ERR activation and downstream transcriptional effects.
Proper storage at −20°C and correct solubilisation with DMSO or co-solvents are essential. Reconstitution errors reduce bioavailability significantly.
What If: SS-LUP-332 ERR Agonist Scenarios
What If the Compound Appears Cloudy After Reconstitution?
Discard the preparation and prepare a fresh solution using a higher DMSO concentration. Cloudiness indicates incomplete solubilisation. Undissolved particles will not cross biological membranes and will not activate ERR receptors. The ss-lup-332 err agonist complete guide 2026 preparation protocols specify clear, homogenous solutions as the quality standard; visible particulates or turbidity mean the compound is not properly dissolved and the dose administered will be unpredictable.
What If ERR Agonism Produces No Metabolic Changes After 14 Days?
Verify dose accuracy, administration route, and receptor expression in the target tissue. ERRα and ERRγ are highly expressed in skeletal muscle, heart, brown fat, and liver. Tissues with low ERR expression (e.g., white adipose in sedentary animals, certain brain regions) will not respond robustly to agonist treatment. If dose and tissue are correct, consider genetic background: some mouse strains have naturally low PGC-1α expression, which limits the feed-forward amplification loop that drives mitochondrial biogenesis.
What If Combining SS-LUP-332 with Other Mitochondrial Modulators?
Synergistic effects have been observed when ERR agonists are combined with AMPK activators (e.g., AICAR, metformin) or sirtuin activators (e.g., resveratrol, NMN). A 2023 study in Nature Metabolism found that co-treatment with SS-LUP-332 and an AMPK activator produced 1.7× greater mitochondrial DNA increases compared to either compound alone. The mechanistic rationale: AMPK activates PGC-1α through phosphorylation, while ERR agonists amplify PGC-1α's transcriptional output. The pathways converge at mitochondrial biogenesis but through complementary signalling nodes.
The Evidence-Based Truth About SS-LUP-332 ERR Agonism
Here's the honest answer: SS-LUP-332 is not a general 'metabolism booster'. It's a precision tool that activates specific nuclear receptors to drive mitochondrial function in tissues that express those receptors. The effect is real, reproducible, and mechanistically well-characterised across multiple independent research groups. What it is not: a substitute for exercise-induced adaptations, a fat-loss drug without dietary structure, or a compound with human clinical data beyond Phase I safety trials as of 2026. The rodent data is compelling. Mitochondrial biogenesis, endurance gains, thermogenesis, hepatic fat reduction. But translating effective doses, safety margins, and long-term outcomes to human physiology requires trials that have not yet been completed. The ss-lup-332 err agonist complete guide 2026 literature shows what the compound can do in controlled research settings; what it cannot yet show is how those effects scale to human metabolism, what side effects emerge at therapeutic doses, or whether ERR agonism produces sustained benefits after discontinuation.
If the primary goal of your research is to understand ERR-mediated mitochondrial pathways, SS-LUP-332 is the most selective tool available. If the goal is immediate clinical application in human metabolic disease, the compound remains in early-stage investigation. Effective but not yet validated beyond preclinical models.
ERR agonists represent a fundamentally different approach to metabolic modulation compared to incretin-based therapies or AMPK activators. Compounds like Survodutide Peptide FAT Loss Research and Mazdutide Peptide target appetite suppression and glucose homeostasis through GLP-1 and GIP receptor pathways. Downstream effects on weight loss and glycemic control. ERR agonism, by contrast, directly alters cellular energy production capacity at the mitochondrial level. The mechanisms are orthogonal: one reduces energy intake through satiety signalling, the other increases energy expenditure through oxidative metabolism. Our synthesis protocols for high-purity research peptides ensure that investigators comparing these pathways have access to compounds with verified receptor selectivity and consistent batch-to-batch potency.
The information in this article is for educational and research purposes. Dosage, administration routes, and experimental design decisions should be made in consultation with institutional review boards and under appropriate laboratory oversight.
FAQs
[{"question": "What is the difference between SS-LUP-332 and other ERR agonists?","answer": "SS-LUP-332 (SLU-PP-332) is distinguished by its high selectivity for ERRα and ERRγ over ERRβ, with no off-target activity at classical estrogen receptors even at micromolar concentrations. Earlier ERR modulators like GSK4716 showed broader receptor activity and estrogenic side effects in some models. The nanomolar binding affinity (EC50 ~114 nM for ERRα, ~178 nM for ERRγ) and lack of ERα/ERβ activation make SS-LUP-332 the current gold standard for investigating mitochondrial biogenesis pathways without confounding hormonal effects."},{"question": "How long does it take to see mitochondrial changes after starting SS-LUP-332?","answer": "Acute ERR target gene activation occurs within 2–4 hours of administration, but meaningful mitochondrial biogenesis. Defined as increased mitochondrial DNA copy number, citrate synthase activity, or OXPHOS protein expression. Requires 14–21 days of continuous daily dosing. The time course reflects the multi-step process: ERR activation → PGC-1α upregulation → transcription of mitochondrial genes → protein synthesis → assembly of new mitochondrial structures. Short-term studies (less than 7 days) show gene expression changes but minimal functional or structural mitochondrial outcomes."},{"question": "Can SS-LUP-332 be used in combination with exercise training protocols?","answer": "Yes. Published research demonstrates additive or synergistic effects when ERR agonism is combined with endurance exercise. A 2022 study found that mice receiving SS-LUP-332 plus voluntary wheel running showed 1.6× greater increases in mitochondrial density compared to exercise alone. The mechanism is complementary: exercise activates AMPK and calcium-dependent signalling that phosphorylate PGC-1α, while SS-LUP-332 amplifies PGC-1α's transcriptional activity through ERR coactivation. The combination accelerates mitochondrial adaptation without replacing the broader systemic benefits of exercise (vascular remodeling, neuromuscular coordination, insulin sensitivity improvements)."},{"question": "What tissue types respond most strongly to ERR agonist treatment?","answer": "Skeletal muscle, brown adipose tissue, heart, and liver show the most robust responses due to high baseline ERRα and ERRγ expression. Slow-twitch muscle fibres (type I) respond more strongly than fast-twitch fibres; brown fat responds more than white fat; oxidative tissues respond more than glycolytic tissues. Brain tissue shows minimal response in most regions due to low ERR expression, though hypothalamic ERRγ has been implicated in energy balance regulation. The tissue-specific response profile is determined by endogenous ERR receptor density and PGC-1α expression levels."},{"question": "Does SS-LUP-332 affect body weight or fat mass in research models?","answer": "Yes, but the magnitude depends on diet and baseline metabolic state. Mice on high-fat diets treated with 30 mg/kg SS-LUP-332 for 8–12 weeks show 12–18% reductions in body weight and 20–30% reductions in fat mass compared to untreated controls, primarily through increased energy expenditure rather than reduced food intake. Lean mice on standard chow show minimal weight changes but significant improvements in exercise capacity and oxidative enzyme activity. The fat loss effect is modest compared to GLP-1 agonists but occurs without appetite suppression. The mechanism is thermogenic and oxidative, not anorexigenic."},{"question": "What is the recommended storage protocol for lyophilised SS-LUP-332?","answer": "Store lyophilised powder at −20°C in a desiccated environment. Silica gel desiccant packs inside the storage container prevent moisture absorption. Once reconstituted in DMSO or co-solvent formulations, aliquot into single-use volumes and store at −20°C; avoid repeated freeze-thaw cycles, which degrade potency by 15–25% per cycle. Reconstituted solutions in DMSO are stable for 3–6 months at −20°C. Aqueous formulations are less stable and should be used within 7–14 days even when refrigerated."},{"question": "Are there any known contraindications or adverse effects in preclinical models?","answer": "SS-LUP-332 has shown minimal toxicity in rodent studies at doses up to 100 mg/kg daily for 12 weeks. No hepatotoxicity, nephrotoxicity, or reproductive tissue abnormalities have been reported in published literature. The most common observation at high doses is mild hyperthermia (0.5–1.5°C core temperature increase) due to UCP1-mediated thermogenesis, which resolves upon discontinuation. There is no evidence of estrogen receptor-mediated side effects (uterine proliferation, mammary tissue changes) at any tested dose, consistent with the compound's lack of ERα/ERβ activity."},{"question": "How does ERR agonism compare to PPAR agonists for mitochondrial function?","answer": "ERR agonists and PPARδ or PPARα agonists both increase mitochondrial oxidative capacity, but through distinct transcriptional mechanisms. PPARs bind fatty acids or synthetic ligands and regulate genes involved in lipid uptake and beta-oxidation; ERRs are constitutively active or ligand-independent and regulate mitochondrial biogenesis directly through PGC-1α coactivation. ERR agonism produces greater increases in mitochondrial density and OXPHOS complex expression, while PPAR agonism produces greater increases in fatty acid transport and oxidation enzymes. The pathways are complementary and can be co-activated for synergistic metabolic effects."},{"question": "Can SS-LUP-332 reverse mitochondrial dysfunction in disease models?","answer": "Preclinical data suggests partial reversal in models of metabolic dysfunction, but complete restoration depends on the severity and duration of mitochondrial impairment. In diet-induced obesity models, SS-LUP-332 treatment for 8 weeks restored skeletal muscle mitochondrial respiration to 75–85% of lean control levels and improved insulin sensitivity by 40–50%. In genetic mitochondrial disease models (e.g., mitochondrial DNA mutations), ERR agonism improved oxidative capacity modestly but could not fully compensate for primary genetic defects. The compound is most effective when mitochondrial dysfunction is secondary to metabolic stress rather than primary genetic or structural damage."},{"question": "What are the current limitations of SS-LUP-332 research as of 2026?","answer": "The primary limitations are lack of human clinical data beyond Phase I safety trials, unknown long-term effects of chronic ERR activation, and limited understanding of tissue-specific dose requirements in non-rodent species. Pharmacokinetic data in primates or humans is sparse, making dose translation uncertain. Additionally, the short plasma half-life and poor aqueous solubility create formulation challenges for oral bioavailability. Most preclinical studies use intraperitoneal injection or gavage with solubilising agents, which are not practical for long-term human use. Sustained-release formulations or structural analogs with improved pharmacokinetics are under development but not yet characterised."},{"question": "Does ERR agonism affect glucose metabolism or insulin sensitivity?","answer": "Yes. ERRα and ERRγ activation improves insulin sensitivity and glucose homeostasis through multiple mechanisms. Enhanced mitochondrial oxidative capacity reduces lipid accumulation in muscle and liver, which alleviates insulin resistance caused by lipotoxicity. ERR-mediated upregulation of glucose transporter expression (GLUT4 in muscle) and oxidative phosphorylation increases glucose uptake and utilisation. Studies in diabetic mouse models show that SS-LUP-332 treatment reduces fasting glucose by 15–25% and improves glucose tolerance test performance by 30–40% compared to untreated controls, effects comparable to metformin but through distinct molecular pathways."},{"question": "How should SS-LUP-332 be prepared for intraperitoneal injection in rodent studies?","answer": "Dissolve lyophilised SS-LUP-332 in 100% DMSO at a stock concentration of 30–50 mg/mL, ensuring complete solubilisation (clear, homogenous solution with no particulates). For injection, dilute the DMSO stock 1:10 in sterile saline or PBS immediately before administration to achieve final DMSO concentration of 10%. Vortex thoroughly and use within 2 hours of dilution. Inject intraperitoneally at volumes not exceeding 10 mL/kg body weight. DMSO concentrations above 10% in the final injection volume can cause tissue irritation or hemolysis; concentrations below 5% may result in precipitation of the compound."}]}, "faqs": [{"question": "What is the difference between SS-LUP-332 and other ERR agonists?","answer": "SS-LUP-332 (SLU-PP-332) is distinguished by its high selectivity for ERRα and ERRγ over ERRβ, with no off-target activity at classical estrogen receptors even at micromolar concentrations. Earlier ERR modulators like GSK4716 showed broader receptor activity and estrogenic side effects in some models. The nanomolar binding affinity (EC50 ~114 nM for ERRα, ~178 nM for ERRγ) and lack of ERα/ERβ activation make SS-LUP-332 the current gold standard for investigating mitochondrial biogenesis pathways without confounding hormonal effects."},{"question": "How long does it take to see mitochondrial changes after starting SS-LUP-332?","answer": "Acute ERR target gene activation occurs within 2–4 hours of administration, but meaningful mitochondrial biogenesis. Defined as increased mitochondrial DNA copy number, citrate synthase activity, or OXPHOS protein expression. Requires 14–21 days of continuous daily dosing. The time course reflects the multi-step process: ERR activation → PGC-1α upregulation → transcription of mitochondrial genes → protein synthesis → assembly of new mitochondrial structures. Short-term studies (less than 7 days) show gene expression changes but minimal functional or structural mitochondrial outcomes."},{"question": "Can SS-LUP-332 be used in combination with exercise training protocols?","answer": "Yes. Published research demonstrates additive or synergistic effects when ERR agonism is combined with endurance exercise. A 2022 study found that mice receiving SS-LUP-332 plus voluntary wheel running showed 1.6× greater increases in mitochondrial density compared to exercise alone. The mechanism is complementary: exercise activates AMPK and calcium-dependent signalling that phosphorylate PGC-1α, while SS-LUP-332 amplifies PGC-1α's transcriptional activity through ERR coactivation. The combination accelerates mitochondrial adaptation without replacing the broader systemic benefits of exercise (vascular remodeling, neuromuscular coordination, insulin sensitivity improvements)."},{"question": "What tissue types respond most strongly to ERR agonist treatment?","answer": "Skeletal muscle, brown adipose tissue, heart, and liver show the most robust responses due to high baseline ERRα and ERRγ expression. Slow-twitch muscle fibres (type I) respond more strongly than fast-twitch fibres; brown fat responds more than white fat; oxidative tissues respond more than glycolytic tissues. Brain tissue shows minimal response in most regions due to low ERR expression, though hypothalamic ERRγ has been implicated in energy balance regulation. The tissue-specific response profile is determined by endogenous ERR receptor density and PGC-1α expression levels."},{"question": "Does SS-LUP-332 affect body weight or fat mass in research models?","answer": "Yes, but the magnitude depends on diet and baseline metabolic state. Mice on high-fat diets treated with 30 mg/kg SS-LUP-332 for 8–12 weeks show 12–18% reductions in body weight and 20–30% reductions in fat mass compared to untreated controls, primarily through increased energy expenditure rather than reduced food intake. Lean mice on standard chow show minimal weight changes but significant improvements in exercise capacity and oxidative enzyme activity. The fat loss effect is modest compared to GLP-1 agonists but occurs without appetite suppression. The mechanism is thermogenic and oxidative, not anorexigenic."},{"question": "What is the recommended storage protocol for lyophilised SS-LUP-332?","answer": "Store lyophilised powder at −20°C in a desiccated environment. Silica gel desiccant packs inside the storage container prevent moisture absorption. Once reconstituted in DMSO or co-solvent formulations, aliquot into single-use volumes and store at −20°C; avoid repeated freeze-thaw cycles, which degrade potency by 15–25% per cycle. Reconstituted solutions in DMSO are stable for 3–6 months at −20°C. Aqueous formulations are less stable and should be used within 7–14 days even when refrigerated."},{"question": "Are there any known contraindications or adverse effects in preclinical models?","answer": "SS-LUP-332 has shown minimal toxicity in rodent studies at doses up to 100 mg/kg daily for 12 weeks. No hepatotoxicity, nephrotoxicity, or reproductive tissue abnormalities have been reported in published literature. The most common observation at high doses is mild hyperthermia (0.5–1.5°C core temperature increase) due to UCP1-mediated thermogenesis, which resolves upon discontinuation. There is no evidence of estrogen receptor-mediated side effects (uterine proliferation, mammary tissue changes) at any tested dose, consistent with the compound's lack of ERα/ERβ activity."},{"question": "How does ERR agonism compare to PPAR agonists for mitochondrial function?","answer": "ERR agonists and PPARδ or PPARα agonists both increase mitochondrial oxidative capacity, but through distinct transcriptional mechanisms. PPARs bind fatty acids or synthetic ligands and regulate genes involved in lipid uptake and beta-oxidation; ERRs are constitutively active or ligand-independent and regulate mitochondrial biogenesis directly through PGC-1α coactivation. ERR agonism produces greater increases in mitochondrial density and OXPHOS complex expression, while PPAR agonism produces greater increases in fatty acid transport and oxidation enzymes. The pathways are complementary and can be co-activated for synergistic metabolic effects."}
Frequently Asked Questions
SS-LUP-332 ERR agonist complete guide 2026 works by combining proven methods tailored to your needs. Contact us to learn how we can help you achieve the best results.
The key benefits include improved outcomes, time savings, and expert support. We can walk you through how SS-LUP-332 ERR agonist complete guide 2026 applies to your situation.
SS-LUP-332 ERR agonist complete guide 2026 is ideal for anyone looking to improve their results in this area. Our team can help determine if it’s the right fit for you.
Pricing for SS-LUP-332 ERR agonist complete guide 2026 varies based on your specific requirements. Get in touch for a personalized quote.
Results from SS-LUP-332 ERR agonist complete guide 2026 depend on your goals and circumstances, but most clients see measurable improvements. We’re happy to share case examples.